research use only
Cat.No.S8348
|
In vitro |
DMSO
: 100 mg/mL
(198.98 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 502.56 | Formula | C31H26N4O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1231889-53-4 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1=C(C=CC=C1N2C=NC3=CC=CC=C3C2=O)C4=C5C6=C(C=C(C=C6)C(C)(C)O)NC5=C(C=C4)C(=O)N | ||
| Targets/IC50/Ki |
BTK
(Cell-free assay) 2.8 nM
TEC
(Cell-free assay) 13 nM
BLK
(Cell-free assay) 20 nM
BMX
(Cell-free assay) 24 nM
TrkA
(Cell-free assay) 30 nM
HER4
(Cell-free assay) 50 nM
ITK
(Cell-free assay) 96 nM
TrkB
(Cell-free assay) 100 nM
RET
(Cell-free assay) 110 nM
LCK
(Cell-free assay) 150 nM
Lyn
(Cell-free assay) 160 nM
TXK
(Cell-free assay) 180 nM
|
|---|---|
| In vitro |
BMS-935177 shows greater than 50-fold selectivity over the SRC family of kinases, including 1100-fold selectivity over SRC itself. Other kinases inhibited with a potency less than 150 nM (50-fold selectivity) included TRKA, HER4, TRKB, and RET. It inhibits calcium flux in human Ramos B cells (IC50 = 27 nM) and inhibits CD69 surface expression in peripheral B cells stimulated with anti-IgM and anti-IgG. However, this compound has no effect on CD69 surface expression in B cells stimulated through the CD40 receptor with CD40 ligand. Against IgG-containing immune complex-driven low affinity activating Fcγ receptor (FcγRIIa and FcγRIII) end points in peripheral blood mononuclear cells (PBMCs), this chemical effectively inhibited TNFα production with an IC50 value of 14 nM.
|
| In vivo |
Plasma protein binding for BMS-935177 is high for all species, with less than 1% free for human. It has excellent oral bioavailability in all preclinical species, from both suspension and solution dosing, despite its low aqueous solubility. The oral bioavailability for this compound with solution dosing ranges from 84% to 100% in rat, mouse, dog, and cynomolgus monkey, with low clearance in single intravenous (iv) infusion studies. When dosed at 2 mg/kg i.v. in mouse and rat, the T1/2 of this chemical is 4 h and 5.1 h respectively.
|
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.